---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-25-000058"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:07:28.800687+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ligand Q3 revenue $115.5M, net income $117.3M; raises FY guidance

## Summary
- Q3 royalties $46.6M, up 47% YoY, driven by Filspari, Ohtuvayre, Qarziba.
- Adjusted EPS $3.09 vs $1.84 YoY; GAAP net income $117.3M ($5.68 diluted).
- FY 2025 core revenue guidance raised to $225M-$235M; core adj. EPS $7.40-$7.65.
- Closed $460M 0.75% convertible notes due 2030; net proceeds ~$445M.
- New royalty investments: $7M for AT220/AT292 rights; $25M in Orchestra BioMed.

## SEC filing metadata
- accession: 0000886163-25-000058
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/0000886163-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/lgnd-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-25-000058
- JSON: https://secwatch.observer/filing/0000886163-25-000058.json
- Plain text: https://secwatch.observer/filing/0000886163-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.